Correction

Correction: CDKL3 promotes osteosarcoma progression by activating Akt/PKB

Aina He1,2,*; Lanjing Ma3,*; Yujing Huang1,*; Haijiao Zhang3; Wei Duan4; Zexu Li3; Teng Fei3*; Junqing Yuan5; Hao Wu6; Liguo Liu7; Yueqing Bai8; Wentao Dai8; Yonggang Wang1; Hongtao Li1; Yong Sun1; Yaling Wang1; Chunyan Wang1; Ting Yuan1*; Qingcheng Yang9; Songhai Tian2*; Min Dong2; Ren Sheng3; Dongxi Xiang10,11,12

1Department of Oncology, Shanghai Jiaotong University Affiliated Sixth People’s Hospital, Shanghai, PR China 2Department of Urology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA 3College of Life and Health Sciences, Northeastern University, Shenyang, PR China 4School of Medicine and Centre for Molecular and Medical Research, Deakin University, Waurn Ponds, Australia 5Department of Pathology, Shanghai Jiaotong University Affiliated Sixth People’s Hospital, Shanghai, PR China 6Department of Vascular Biology, Boston Children’s Hospital, Boston, MA, USA 7Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China 8Shanghai Center for Bioinformation Technology and Shanghai Engineering Research Center of Pharmaceutical Translation, Shanghai Industrial Technology Institute, Shanghai, PR China 9Department of Orthopedics, Shanghai Jiaotong University Affiliated Sixth People’s Hospital, Shanghai, PR China 10Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA 11Department of Medicine, Harvard Medical School, Boston, MA, USA 12Shanghai Research Center of Biliary Tract Disease Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Correspondence: anna_1188@126.com; shengren1211@126.com; dxiang@bwh.harvard.edu

*Aina He, Lanjing Ma, and Yujing Huang contributed equally to this work.

DOI https://doi.org/10.26508/lsa.202201656 | Received 14 September 2022 | Accepted 21 September 2022 | Published online 21 October 2022


In the published article, there were three errors:

1. We designed the primers for PDX1 using GenBank entry AF049893.1. This sequence was entered in 1997 as human Pdx1, but it is actually rat Pdx1. We were unaware of this error and observed a negligible effect on PDX1, so we removed PDX1 from Fig 5B. This does not have any effect on the other conclusions in Fig 5B.

2. In Fig 6C, lower row, patient (a) the exact CDKL3-staining image was placed back.

3. On page 10, “The insert with triple-HA tag at their N termini (with GSGSGSEF as linker) was further cloned to pcDNA3.1 vector via Gibson Assembly (2621; New England Biolabs) and sequenced using primers 5’-GGGCTGATAAAGAAGGCAGAAAATT; 5’-TGCCTTGGCCTCCCAAAGTGCA.” The correct primers should read as follows: 5’-CGCAAATGGGCGGTAGGCGTG; 5’-GCTGGGGTAGTTCTTCCTCAAGTTC.

The conclusions of this article remain unchanged.

Figure 5. (B) The expression patterns of mTORC1 and FoxO downstream target genes confirm that CDKL3 regulates both pathways at the transcription level. Cells were cultured under the regular growth condition.

Figure 6. (C) Representative immunohistochemistry (IHC) images of OS biopsies with different levels of CDKL3 expression on an OS microarray containing 152 primary OS tissues samples. Scale bar = 500 μm.